Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Immunic, Inc. received an updated ownership report from 683 Capital entities and Ari Zweiman. As of December 31, 2025, they may be deemed to beneficially own warrants exercisable for 7,500,000 shares of Immunic common stock. Based on shares outstanding plus these warrant shares, this represents about 5.9% of the company’s common stock. The filing states that the securities are not held for the purpose of changing or influencing control of Immunic.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake in Immunic, Inc. (IMUX) does 683 Capital report on this Schedule 13G/A?
The reporting persons disclose beneficial ownership of warrants for 7,500,000 Immunic common shares, representing about 5.9% of the outstanding common stock. This percentage is calculated using Immunic’s reported 120,284,724 shares outstanding plus the warrant shares.
Who are the reporting persons in the Immunic, Inc. (IMUX) Schedule 13G/A amendment?
The filing lists 683 Capital Partners, LP, 683 Capital Management, LLC, and Ari Zweiman as reporting persons. 683 Capital Partners holds the warrants, while 683 Capital Management and Ari Zweiman may be deemed beneficial owners through their management roles.
How is the 5.9% beneficial ownership in Immunic (IMUX) calculated in this filing?
The 5.9% figure is based on 120,284,724 Immunic common shares outstanding as of November 11, 2025, plus 7,500,000 shares issuable upon exercise of currently exercisable warrants held by the reporting persons, as described in the ownership section.
Does 683 Capital indicate an intent to influence control of Immunic, Inc. (IMUX)?
The certification states the securities were not acquired and are not held to change or influence control of Immunic. It also notes they are not held in connection with any control-related transaction, other than activities related to a nomination under Rule 240.14a-11.
What type of Immunic (IMUX) securities are referenced in this Schedule 13G/A?
The filing concerns warrants to purchase Immunic common stock, par value $0.0001 per share. These warrants are described as currently exercisable into 7,500,000 shares, which are included in the reporting persons’ beneficial ownership calculation.
What is the event date for the Immunic, Inc. (IMUX) ownership reported by 683 Capital?
The statement identifies December 31, 2025 as the relevant ownership date. As of that date, the reporting persons may be deemed to beneficially own warrants exercisable into 7,500,000 Immunic common shares, representing approximately 5.9% of the class.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
IMMUNIC, INC.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
4525EP101
(CUSIP Number)
12/31/2025
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
SCHEDULE 13G
CUSIP No.
4525EP101
1
Names of Reporting Persons
683 CAPITAL MANAGEMENT, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
7,500,000.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
7,500,000.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
7,500,000.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.9 %
12
Type of Reporting Person (See Instructions)
IA
SCHEDULE 13G
CUSIP No.
4525EP101
1
Names of Reporting Persons
683 CAPITAL PARTNERS, LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
7,500,000.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
7,500,000.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
7,500,000.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.9 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP No.
4525EP101
1
Names of Reporting Persons
Zweiman Ari
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
7,500,000.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
7,500,000.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
7,500,000.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.9 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
IMMUNIC, INC.
(b)
Address of issuer's principal executive offices:
1200 Avenue of the Americas, Suite 200, New York, New York 10036
Item 2.
(a)
Name of person filing:
683 Capital Management, LLC
683 Capital Partners, LP
Ari Zweiman
Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."
(b)
Address or principal business office or, if none, residence:
The principal business address for each of the Reporting Persons is 1700 Broadway, Suite 4200, New York, NY 10019.
(c)
Citizenship:
683 Capital Management, LLC - DELAWARE
683 Capital Partners, LP - DELAWARE
Ari Zweiman - UNITED STATES
(d)
Title of class of securities:
Common Stock, par value $0.0001 per share
(e)
CUSIP No.:
4525EP101
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
As of December 31, 2025, 683 Capital Partners, LP beneficially owned warrants to purchase 7,500,000 shares of Common Stock which are currently exercisable.
683 Capital Management, LLC, as the investment manager of 683 Capital Partners, LP, may be deemed to have beneficially owned the warrants to purchase 7,500,000 shares of Common Stock beneficially owned by 683 Capital Partners, LP.
Ari Zweiman, as the Managing Member of 683 Capital Management, LLC, may be deemed to have beneficially owned the warrants to purchase 7,500,000 shares of Common Stock beneficially owned by 683 Capital Management, LLC.
The following percentage is based on 120,284,724 shares of Common Stock outstanding as of November 11, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 13, 2025, plus 7,500,000 shares of Common Stock issuable upon exercise of currently exercisable warrants held by the Reporting Persons.
As of December 31, 2025, the Reporting Persons may be deemed to have beneficially owned 7,500,000 shares of Common Stock, constituting approximately 5.9% of the outstanding shares of Common Stock.
(b)
Percent of class:
5.9%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
See Cover Pages Items 5-9.
(ii) Shared power to vote or to direct the vote:
See Cover Pages Items 5-9.
(iii) Sole power to dispose or to direct the disposition of:
See Cover Pages Items 5-9.
(iv) Shared power to dispose or to direct the disposition of:
See Cover Pages Items 5-9.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
See Exhibit 99.1 to Schedule 13G filed on August 8, 2025.
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
